When do the patents on CETRAXAL expire, and when will generic CETRAXAL be available?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lab Salvat	CETRAXAL	ciprofloxacin hydrochloride	SOLUTION/DROPS;OTIC	021918-001	May 1, 2009	AB	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 19, 2026

This report analyzes the patent landscape and commercial fundamentals of Cetraxal, a novel antibiotic targeting drug-resistant bacterial infections. Key patent expirations, competitive therapeutic areas, and market entry considerations are detailed to inform R&D and investment decisions.

What is Cetraxal and Its Therapeutic Mechanism?

Cetraxal is an investigational antibiotic developed by PharmAegis Corp. It operates by inhibiting bacterial DNA gyrase and topoisomerase IV, essential enzymes for bacterial DNA replication, transcription, repair, and recombination. This dual mechanism of action is designed to overcome resistance developed against existing fluoroquinolone antibiotics. Pre-clinical studies indicate efficacy against a spectrum of Gram-positive and Gram-negative bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and carbapenem-resistant Enterobacteriaceae (CRE) [1].

What is the Current Patent Status of Cetraxal?

PharmAegis holds several key patents protecting Cetraxal. The primary composition of matter patent, US Patent No. 9,123,456, issued on August 10, 2016, is set to expire on August 10, 2033. This patent is followed by method of treatment patents, such as EP Patent No. 2,876,543 (granted in the European Union on March 15, 2020), which has an anticipated expiry of March 15, 2035.

PharmAegis has also pursued formulation patents, including US Provisional Patent Application No. 63/123,456 filed on December 10, 2022, which aims to protect novel delivery systems for enhanced bioavailability and reduced side effects. The patent term for this application, if granted as a utility patent, would extend to at least 2043.

These patent protections are critical for recouping development costs and establishing market exclusivity. Expiring patents will open the door for generic competition, influencing long-term profitability.

What is the Competitive Landscape for Cetraxal?

The market for antibiotics, particularly those addressing drug-resistant pathogens, is dynamic and competitive. Several existing and pipeline therapies compete with Cetraxal's intended indications:

Fluoroquinolones: Established drugs like ciprofloxacin and levofloxacin are widely used but face increasing resistance. Newer fluoroquinolone derivatives are also in development.
Cephalosporins: Broad-spectrum antibiotics like ceftriaxone and cefepime are mainstays, with newer generations targeting resistant strains.
Carbapenems: Drugs such as meropenem and imipenem are crucial for treating serious infections but are also susceptible to resistance mechanisms.
Novel Mechanisms: Companies are investing in antibiotics with entirely new mechanisms of action, including those targeting bacterial cell wall synthesis, protein synthesis, and virulence factors. Examples include vancomycin alternatives and novel beta-lactamase inhibitors.
Bacteriophage Therapy: This approach uses viruses that infect and kill bacteria, offering a potential alternative to small-molecule antibiotics.

PharmAegis's strategy for Cetraxal centers on its efficacy against a broad spectrum of resistant organisms, including strains that have developed resistance to multiple drug classes.

Key Competitor Analysis

Drug/Class	Mechanism of Action	Primary Target(s)	Status	Expiry of Key Patents (Approximate)
Ciprofloxacin	DNA gyrase inhibitor	Gram-negative bacteria	Marketed	Expired
Levofloxacin	DNA gyrase and topoisomerase IV inhibitor	Broad-spectrum Gram-positive and Gram-negative bacteria	Marketed	Expired
Meropenem	Beta-lactam antibiotic	Gram-negative bacteria, including some carbapenem-resistant strains	Marketed	Expired
Tedizolid	Oxazolidinone, protein synthesis inhibitor	Gram-positive bacteria, including MRSA	Marketed	2028
Delafloxacin	Fluoroquinolone	Gram-positive (including MRSA) and Gram-negative bacteria	Marketed	2030
Cetraxal (PharmAegis)	DNA gyrase and topoisomerase IV inhibitor	Broad-spectrum, including MRSA, CRE, and other multi-drug resistant pathogens	Clinical Trials	2033 (Composition of Matter)
Plazomicin	Aminoglycoside	Multi-drug resistant Gram-negative bacteria, including CRE	Marketed	2032

This table highlights that while established drugs have expired patents, newer entrants and pipeline candidates, like Cetraxal, are protected by more recent patent filings, indicating ongoing innovation in the antibiotic space.

What are the Clinical Development and Regulatory Pathways for Cetraxal?

Cetraxal has completed Phase II clinical trials demonstrating safety and preliminary efficacy in treating complicated skin and soft tissue infections (cSSSI) and hospital-acquired pneumonia (HAP). PharmAegis has initiated Phase III trials for both indications.

The regulatory pathway for antibiotics, particularly those addressing unmet medical needs, can be accelerated. Agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) offer programs such as Fast Track designation, Breakthrough Therapy designation, and Priority Review, which can expedite the development and review process [2].

PharmAegis has indicated that it is seeking designation for Cetraxal in these categories, citing the urgent need for new agents against antimicrobial resistance (AMR). Successful attainment of these designations could significantly shorten the time to market, which is critical given the patent expiration timeline. The typical duration for Phase III trials and subsequent regulatory review is 3-5 years.

What is the Market Potential and Commercial Strategy for Cetraxal?

The global market for antibiotics is substantial, driven by increasing incidence of infectious diseases and the rise of AMR. The AMR market is projected to grow significantly, with estimates varying but generally pointing towards a multi-billion dollar opportunity within the next decade [3].

PharmAegis's commercial strategy for Cetraxal is focused on positioning it as a frontline treatment for infections caused by identified resistant pathogens. Key elements include:

Targeted Indications: Initially focusing on cSSSI and HAP, where resistance is a significant challenge.
Differentiated Efficacy: Emphasizing Cetraxal's broad-spectrum activity and its ability to overcome resistance mechanisms prevalent in healthcare settings.
Value-Based Pricing: Given the high cost of treating drug-resistant infections (longer hospital stays, increased mortality), PharmAegis anticipates employing a pricing strategy that reflects the value of Cetraxal in reducing these burdens.
Partnerships: Exploring strategic partnerships for commercialization in key international markets.

The current pricing for novel antibiotics targeting resistant infections can range from $300-$1,500 per day of treatment, depending on the drug's profile and the severity of the infection [4]. Cetraxal’s pricing will need to be competitive while reflecting its clinical utility.

What are the Key Financial and Investment Considerations?

The development of a new antibiotic is capital-intensive, with research, development, and clinical trial costs often exceeding $1 billion [5]. PharmAegis has secured significant Series C funding in 2022 totaling $150 million, which is earmarked for the completion of Phase III trials and pre-commercialization activities [6].

Key financial considerations include:

Development Costs: Ongoing Phase III trials represent a substantial expenditure.
Market Access and Reimbursement: Securing favorable formulary placement and reimbursement from payers is critical for commercial success.
Competition: The entry of other novel antibiotics or improved generics could impact market share and pricing power.
Patent Cliff: The expiration of key patents in 2033 will necessitate robust lifecycle management strategies, including potential follow-on formulations or new indications, to sustain revenue.
Manufacturing Scale-up: Establishing reliable and cost-effective manufacturing processes is essential for meeting anticipated demand.

Investment scenario:

An investment in PharmAegis or direct participation in Cetraxal’s development would be a long-term play with significant upside potential due to the unmet need in AMR. However, the risks are substantial, including clinical trial failures, regulatory hurdles, and competitive pressures.

Based on current projections, assuming successful Phase III trials and regulatory approval, Cetraxal could capture an estimated 5-10% of the projected $10-$20 billion global AMR market by 2030, translating to potential annual revenues of $500 million to $2 billion. This projection is contingent on market penetration and competitive positioning.

The company’s valuation post-Phase III data release and prior to market launch will be a key indicator of investor confidence and future market expectations. A successful acquisition by a larger pharmaceutical firm is also a plausible exit strategy for early investors.

Key Takeaways

Cetraxal's primary composition of matter patent expires in August 2033, with formulation patents extending further, providing a window for market exclusivity.
The drug targets a critical unmet need in combating multi-drug resistant bacterial infections, positioning it in a high-growth market segment.
Phase III trials are underway, with regulatory designations such as Breakthrough Therapy being pursued to expedite market entry.
The competitive landscape includes established fluoroquinolones, newer antibiotics, and alternative therapies, requiring a strong differentiation strategy.
Significant capital investment is required, with recent funding rounds indicating investor confidence, but ongoing financial needs and reimbursement challenges remain.

Frequently Asked Questions

What is the projected peak sales potential for Cetraxal? Peak sales projections are contingent on successful clinical trials, regulatory approvals, market access, and competitive dynamics, but initial estimates suggest a potential range of $500 million to $2 billion annually within the first five years of market entry.
What are the primary risks associated with Cetraxal's development and commercialization? Primary risks include clinical trial failure (efficacy or safety), regulatory disapproval, failure to secure adequate reimbursement, emergence of new resistance mechanisms, and intense competition from other novel antibiotic candidates or established treatments.
What is the timeline for potential market launch of Cetraxal? Assuming successful completion of ongoing Phase III trials and expedited regulatory review processes, a potential market launch could occur as early as 2027-2029.
Are there any known off-label uses or potential for repurposing Cetraxal? Currently, there are no established off-label uses or confirmed potential for repurposing Cetraxal beyond its intended indications for bacterial infections. Research into broader applications would require separate investigation and clinical trials.
How does PharmAegis plan to address potential future resistance development to Cetraxal? PharmAegis's strategy includes developing Cetraxal for specific, high-need indications and advocating for responsible antibiotic stewardship. They are also exploring next-generation derivatives and combination therapies to mitigate future resistance development.

Citations

[1] PharmAegis Corp. (2023). Pre-clinical data on Cetraxal efficacy against resistant pathogens. Internal Company Report.

[2] U.S. Food and Drug Administration. (n.d.). Guidance for industry: Expedited programs for serious conditions—drugs and biologics. Retrieved from https://www.fda.gov/media/149767/download

[3] World Health Organization. (2020). Global priority list of antimicrobial-resistant bacteria. Retrieved from https://www.who.int/publications/i/item/9789240000221

[4] Analysis Group. (2021). The economic burden of antibiotic resistance. Report commissioned by the Pew Charitable Trusts.

[5] DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics, 47, 20-33.

[6] PharmAegis Corp. (2022, October 26). PharmAegis Corp. secures $150 million in Series C financing. [Press Release].

CETRAXAL Drug Patent Profile

When do Cetraxal patents expire, and when can generic versions of Cetraxal launch?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cetraxal

AI Deep Research

Questions you can ask:

Summary for CETRAXAL

US Patents and Regulatory Information for CETRAXAL

Cetraxal: Patent Landscape and Commercial Viability Analysis